EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Personalized Antihypertensive Treatment Optimization With Smartphone‐Enabled Remote Precision Dosing of Amlodipine During the COVID‐19 Pandemic (PERSONAL‐CovidBP Trial)

David J Collier iD, Mike Taylor iD, Thomas Godec iD, Julian Shiel, Rebecca James, Yasmin Chowdury, Patrizia Ebano, Vivienne Monk iD, Mital Patel iD, Jane Pheby, Ruby Pheby iD, Amanda Foubister und 11 weitere

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.123.030749 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von David J Collier und 22 weiteren Autor:innen. Beteiligte Einrichtung: William Harvey Research Institute Queen Mary University of London London UK. Hauptthemen laut MEDLINE: COVID-19, Hypertension. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background The objective of the PERSONAL‐CovidBP (Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension: Pilot Study for Remote Medical Management of Hypertension During the COVID‐19 Pandemic) trial was to assess the efficacy and safety of smartphone‐enabled remote precision dosing of amlodipine to control blood pressure (BP) in participants with primary hypertension during the COVID‐19 pandemic. Methods and Results This was an open‐label, remote, dose titration trial using daily home self‐monitoring of BP, drug dose, and side effects with linked smartphone app and telemonitoring. Participants aged ≥18 years with uncontrolled hypertension (5–7 day baseline mean ≥135 mm Hg systolic BP or ≥85 mm Hg diastolic BP) received personalized amlodipine dose titration using novel (1, 2, 3, 4, 6, 7, 8, 9 mg) and standard (5 and 10 mg) doses daily over 14 weeks. The primary outcome of the trial was mean change in systolic BP from baseline to end of treatment. A total of 205 participants were enrolled and mean BP fell from 142/87 (systolic BP/diastolic BP) to 131/81 mm Hg (a reduction of 11 (95% CI, 10–12)/7 (95% CI, 6–7) mm Hg, P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HypertensionAdolescentAdultHumansAmlodipineAntihypertensive AgentsBlood PressureEssential HypertensionPandemicsPilot ProjectsSmartphoneTreatment Outcome

Stichwörter der Autor:innen

amlodipinehome blood pressurehypertensionpersonalized dose titrationremote care

Substanzen

AmlodipineAntihypertensive Agents

Autor:innen und Institutionen

  • William Harvey Research Institute Queen Mary University of London London UK.
  • Closed Loop Medicine London UK.
  • TrialsConnect London UK.
  • Imperial College Clinical Trials Unit, School of Public Health, Imperial College London London UK.
  • Wolfson Institute of Population Health Queen Mary University of London London UK.
  • Nuffield Department of Primary Care Health Sciences University of Oxford Oxford UK.

ORCID-Profile: David J Collier, Mike Taylor, Thomas Godec, Vivienne Monk, Mital Patel, Ruby Pheby, Manish Saxena, Leanne Richardson, James Siddle, Paul Goldsmith, Neil R Poulter, Rhian Gabe, Richard J McManus, Mark J Caulfield

Förderung

  • Medical Research Council
  • Wellcome Trust

Zitieren

APA

Collier, D. J., Taylor, M., Godec, T., Shiel, J., James, R., Chowdury, Y., Ebano, P., Monk, V., Patel, M., Pheby, J., Pheby, R., Foubister, A., David, C., Saxena, M., Richardson, L., Siddle, J., Timlin, G., Goldsmith, P., Deeming, N., …, & Caulfield, M. J. (2024). Personalized Antihypertensive Treatment Optimization With Smartphone‐Enabled Remote Precision Dosing of Amlodipine During the COVID‐19 Pandemic (PERSONAL‐CovidBP Trial). Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.030749

Vancouver

Collier DJ, Taylor M, Godec T, Shiel J, James R, Chowdury Y, et al. Personalized Antihypertensive Treatment Optimization With Smartphone‐Enabled Remote Precision Dosing of Amlodipine During the COVID‐19 Pandemic (PERSONAL‐CovidBP Trial). Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.030749

BibTeX
@article{Collier2024,
  author = {Collier, David J and Taylor, Mike and Godec, Thomas and Shiel, Julian and James, Rebecca and Chowdury, Yasmin and Ebano, Patrizia and Monk, Vivienne and Patel, Mital and Pheby, Jane and Pheby, Ruby and Foubister, Amanda and David, Clovel and Saxena, Manish and Richardson, Leanne and Siddle, James and Timlin, Gregor and Goldsmith, Paul and Deeming, Nicholas and Poulter, Neil R and Gabe, Rhian and McManus, Richard J and Caulfield, Mark J},
  title = {Personalized Antihypertensive Treatment Optimization With Smartphone‐Enabled Remote Precision Dosing of Amlodipine During the COVID‐19 Pandemic (PERSONAL‐CovidBP Trial)},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.123.030749}
}
Kostenlos starten →